Page 35 - Read Online

Page 12 of 15 Sabol et al. J Cancer Metastasis Treat 2021;7:20 https://dx.doi.org/10.20517/2394-4722.2021.35

Financial support and sponsorship
This work was supported by the National Institutes of Health (R37-CA251763 to J.D.C.)), the Arkansas
COBRE program (NIGMS P20GM125503) to J.D.C., a Scholar Award by the American Society of
Hematology Scholar Award (to J.D.C), and a Brian D. Novis Award by the International Myeloma
Foundation (to J.D.C.).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 2015;125:3049-58. DOI PubMed
PMC
2. Rajkumar SV. Myeloma today: Disease definitions and treatment advances. Am J Hematol 2016;91:90-100. DOI PubMed PMC
3. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia
2009;23:3-9. DOI PubMed PMC
4. Mateos MV, González-Calle V. Smoldering multiple myeloma: Who and when to treat. Clin Lymphoma Myeloma Leuk 2017;17:716-
22. DOI PubMed
5. Mouhieddine TH, Weeks LD, Ghobrial IM. Monoclonal gammopathy of undetermined significance. Blood 2019;133:2484-94. DOI
PubMed
6. Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple
myeloma. Semin Hematol 2011;48:4-12. DOI PubMed PMC
7. Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015;125:3069-75. DOI PubMed PMC
8. Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: Definition, presentation, and treatment. Curr Oncol Rep
2019;21:8. DOI PubMed PMC
9. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from
bench to bedside. Blood Cancer J 2018;8:7. DOI PubMed PMC
10. Silbermann R, Roodman GD. Myeloma bone disease: Pathophysiology and management. J Bone Oncol 2013;2:59-69. DOI PubMed
PMC
11. Delgado-calle J. Osteocytes and their messengers as targets for the treatment of multiple myeloma. Clinic Rev Bone Miner Metab
2017;15:49-56. DOI
12. Macedo F, Ladeira K, Pinho F, et al. Bone metastases: An overview. Oncol Rev 2017;11:321. DOI PubMed PMC
13. Delgado-Calle J, Kurihara N, Atkinson EG, et al. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive
activity mediated by direct effects on osteoclasts. Oncotarget 2019;10:2709-21. DOI PubMed PMC
14. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple
myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018;19:370-81. DOI
PubMed
15. Delgado-Calle J, Anderson J, Cregor MD, et al. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple
myeloma-induced bone disease without affecting tumor growth. Leukemia 2017;31:2686-94. DOI PubMed PMC
16. McDonald MM, Reagan MR, Youlten SE, et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture
resistance in multiple myeloma. Blood 2017;129:3452-64. DOI PubMed PMC
17. Eda H, Santo L, Wein MN, et al. Regulation of sclerostin expression in multiple myeloma by Dkk-1: A potential therapeutic strategy
for myeloma bone disease. J Bone Miner Res 2016;31:1225-34. DOI PubMed PMC
18. Croucher PI, McDonald MM, Martin TJ. Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer 2016;16:373-86.
DOI PubMed
19. Hideshima T, Anderson KC. Signaling pathway mediating myeloma cell growth and survival. Cancers (Basel) 2021;13:216. DOI
PubMed PMC
20. Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma. Curr Opin Oncol 2020;32:170-5. DOI PubMed
21. Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev